Fatty Liver News and Research

Latest Fatty Liver News and Research

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company focused on the development and commercialization of a once-daily, oral therapy for the treatment of liver diseases, announced today that it has entered into a Research, Option and License Agreement ("License Agreement") and a Share Purchase Agreement with One Way Liver Genomics S.L., for the development of a non-invasive, blood-based companion diagnostic tool.

8 Jul 2015

Fructose stimulates reward system in the brain to a lesser degree than glucose

Fructose not only results in a lower level of satiety, it also stimulates the reward system in the brain to a lesser degree than glucose. This may cause excessive consumption accompanied by effects that are a risk to health, report researchers from the University of Basel in a study published in the scientific journal PLOS ONE. Various diseases have been attributed to industrial fructose in sugary drinks and ready meals.

26 Jun 2015

High fructose consumption can lead to uncontrolled growth of cardiomyocytes, heart attack

'Walk through any supermarket and take a look at the labels on food products, and you'll see that many of them contain fructose, often in the form of sucrose (table sugar)' -- that's how Wilhelm Krek, professor for cell biology at ETH Zurich's Institute for Molecular Health Sciences, summarises the problem with today's nutrition.

18 Jun 2015

Daily sugar-sweetened beverage habit may increase NAFLD risk

A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers from the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HRNCA) at Tufts University report today in the Journal of Hepatology.

8 Jun 2015

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

Scientists from the Florida campus of The Scripps Research Institute have been awarded nearly $2.2 million by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health to advance an innovative approach to the treatment of obesity, a serious health problem that affects more than one-third of all Americans.

28 May 2015

Galmed reports net loss of $2.5 million for first quarter 2015

13 May 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Exalenz Bioscience, a leader in developing and marketing of non-invasive medical devices for diagnosing and monitoring a range of gastrointestinal and liver diseases, today announced the initiation of a clinical study evaluating the potential of its BreathID test to diagnose nonalcoholic steatohepatitis (NASH).

6 May 2015

Study shows NASH linked to 50% higher death rates compared with NAFLD

Results from a large population-based cohort of almost a million people in the UK found that the chances of dying from non-alcoholic steatohepatitis (NASH), over a 14-year period, was approximately 50% higher than for those with non-alcoholic fatty liver disease (NAFLD).

25 Apr 2015

Diabetes drug liraglutide could prove to be a new treatment option for NASH

A drug approved to treat type 2 diabetes could prove to be a powerful new treatment option for non-alcoholic steatohepatitis (NASH), according to research presented today at The International Liver Congress 2015. Results from a randomised controlled trial showed liraglutide met the primary endpoint of histological clearance of NASH, and a reduction in the progression of fibrosis.

23 Apr 2015

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Data presented today at The International Liver Congress 2015 demonstrates that remogliflozin etabonate, an investigational drug in type 2 diabetes, is a potential treatment option for the management of patients with non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Data revealed today at The International Liver Congress 2015 show that non-alcoholic fatty liver disease (NAFLD) plays a role in the early stages of coronary atherosclerosis and in its more severe form it can also promote the development of coronary artery calcification (CAC).

23 Apr 2015

Study supports use of vitamin E as effective treatment for NASH

Results revealed today at The International Liver Congress 2015 show that vitamin E (d-alpha-tocopherol) is an effective treatment for non-alcoholic steatohepatitis (NASH). NASH occurs when the liver becomes inflamed due to the accumulation of fat. Over time, persistent inflammation can lead to the formation of fibrous scar tissue in the liver and around its blood vessels, which can eventually cause cirrhosis.

23 Apr 2015

Study: Alginate-enriched bread can reduce fat digestion, circulatory lipids in NAFLD patients

A study revealed today at The International Liver Congress 2015 has demonstrated that alginate-enriched bread has the potential to inhibit fat digestion and circulatory lipids in patients with non-alcoholic fatty liver disease (NAFLD).

23 Apr 2015

May issues of AGA's journals highlight important research updates on liver disease

The May issues of AGA's journals -- Clinical Gastroenterology and Hepatology and Gastroenterology -- highlight important research updates on the most deadly forms of liver disease.

23 Apr 2015

Exercise benefits obese, overweight people with NAFLD

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease in the western world. A new study published in the Journal of Hepatology shows that exercise, regardless of frequency or intensity, benefits obese and overweight adults with NAFLD.

8 Apr 2015

NASH patients more likely to have increased intestinal permeability, shows study

Non-alcoholic steatohepatitis (NASH), the more severe form of non-alcoholic fatty liver disease (NAFLD) that can progress to liver fibrosis and cirrhosis, is associated with leakiness of the intestinal wall, which in turn may worsen liver disease, according to research published in Cellular and Molecular Gastroenterology and Hepatology, the new basic science journal of the American Gastroenterological Association.

3 Apr 2015

Scientists develop computer model to predict how liver stores fat

As part of an effort to understand how an experimental drug for atherosclerosis causes the build-up of fat in the liver, scientists have developed a computer model that can predict how the rate at which liver stores fat in response to various situations. Being able to model liver fat storage gives researchers a way to predict the side effects of drugs and environmental factors at much earlier stages in the research and drug development process, possibly reducing the number of experiments involving animal models.

2 Apr 2015

FGF21 protein can boost regenerative effects of human PPARα

Researchers at UC Davis have illuminated an important distinction between mice and humans: how human livers heal. The difference centers on a protein called PPARα, which activates liver regeneration. Normally, mouse PPARα is far more active and efficient than the human form, allowing mice to quickly regenerate damaged livers.

1 Apr 2015

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

DURECT Corporation today announced that it has initiated a multi-dose Phase 1 clinical trial of an oral formulation of DUR-928, the lead molecule in DURECT's Epigenomic Regulator Program.

30 Mar 2015

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint.

27 Mar 2015

Fatty Liver News and Research

Latest Fatty Liver News and Research

Galmed signs License Agreement for development of blood-based companion diagnostic tool

Fructose stimulates reward system in the brain to a lesser degree than glucose

High fructose consumption can lead to uncontrolled growth of cardiomyocytes, heart attack

Daily sugar-sweetened beverage habit may increase NAFLD risk

TSRI scientists awarded $2.2 million NIH grant to advance innovative approach to obesity treatment

Galmed reports net loss of $2.5 million for first quarter 2015

Exalenz Bioscience investigates clinical utility of BreathID test to diagnose NASH

Study shows NASH linked to 50% higher death rates compared with NAFLD

Diabetes drug liraglutide could prove to be a new treatment option for NASH

Remogliflozin etabonate: A potential treatment option for management of NASH and NAFLD

Non-alcoholic fatty liver disease can promote development of coronary artery calcification

Study supports use of vitamin E as effective treatment for NASH

Study: Alginate-enriched bread can reduce fat digestion, circulatory lipids in NAFLD patients

May issues of AGA's journals highlight important research updates on liver disease

Exercise benefits obese, overweight people with NAFLD

NASH patients more likely to have increased intestinal permeability, shows study

Scientists develop computer model to predict how liver stores fat

FGF21 protein can boost regenerative effects of human PPARα

DURECT initiates DUR-928 multi-dose Phase 1 clinical trial for NAFLD, NASH and AKI

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Fatty Liver News and Research

Latest Fatty Liver News and Research

Leveraging the Radian ASAP in standard casework

A journey through science, software, and innovation: Insights from the Bruker software team

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Newsletters you may be interested in